Calcium channel blockers (CCBs), which are used clinically for treatment of angina and hypertension, are known to inhibit calcium influx into arterial smooth muscle cells and thereby decrease smooth muscle cell contraction. In addition, they prevent cholesteryl ester (CE) accumulation, the hallmark of human atherosclerosis, in arteries of cholesterol-fed animals by cellular mechanisms that remain undefined. The role of CCBs as antiatherosclerotic agents has not been defined. Most studies have demonstrated an inhibitory effect of CCBs on atherogenesis in cholesterol-fed rabbits.5,6 Although one report showed no effect on atherogenesis by CCB administration, the animals used in this study were fed a diet containing very large quantities of cholesterol.7 Despite some differences in results, the majority of the reports to date have shown that CCBs are efficacious as antiatherosclerotic agents in animal models of atherosclerosis. As yet, no studies have the reported effects of CCBs on the atherogenic process, including intracellular cholesterol metabolism, in human arterial tissue.
Within 2 hours, samples were stored at -700 C. Samples were kept frozen for a maximum of 2 weeks for enzyme assays. Previous results in our laboratory have demonstrated that CE enzyme activities, cyclic AMP, and lipid are not altered or oxidized after this freezethawing procedure. After thawing, adventitial tissue was trimmed, and the endothelial surface was gently removed by scraping. The remaining layer (intima media) was homogenized with the use of a tissue chopper and resuspended in sucrose buffer. 10 The activities of the enzymes involved in the CE cycle, intracellular cyclic AMP levels, and lipid content were assayed together in one aortic homogenate. Generally, three to four separate analyses were performed in this manner. The accuracy of adventitial and endothelial removal was verified by tissue sectioning and microscopic examination. In addition, we determined microscopically whether the aortic tissue contained large numbers of macrophages or T lymphocytes in the patient samples studied. (Figure 1 ). Baseline serum cholesterol levels were not affected by drug treatment (200±54 mg/dl in CCB patients vs. 182±50 mg/dl in controls). Arterial CE synthetic activity was not altered in patients on CCBs (Figure 1) .
Cyclic AMP levels were also measured in human arterial cells to determine whether increased CE hydrolysis was accompanied by increased cyclic AMP levels, since activation of arterial CE hydrolase occurs only if cyclic AMP levels are elevated.'9'20 We observed a threefold increase in intracellular cyclic AMP levels in arterial cells obtained from patients on CCBs as compared with untreated patients (0.75±0.15 pmol/ mg protein in controls vs. 2.8±0.80 pmol/mg protein in CCB patients, mean±SD, p<0.05). There was a positive correlation between arterial cyclic AMP levels and CE hydrolytic activity in CCB-treated patients as shown in Figure 2 .
Consistent with the increase in arterial CE hydrolytic activity in CCB-treated patients, both the free and esterified cholesterol content of aortic tissue was significantly reduced in patients taking CCBs compared with untreated patients (Figure 3) . Finally, we also observed that diltiazem (which most patients in this study were given) can also decrease free and esterified cholesterol levels in lipid-laden cultured arterial smooth muscle cells (Figure 4 ), as seen with nifedipine. 8 The mechanism responsible for this increased mobilization of lipid from these cells appears to be associated with (Figure 1 ) and that CCBs can reduce the actual mass of free and esterified cholesterol from human aortic tissue ( Figure 3 ) and in lipid-laden smooth muscle cells in vitro (Figure 4) . The enhanced hydrolysis is accompanied by increased levels of intracellular cyclic AMP (Figure 2) were treated on days 0, 3, and 6 with 100 pg/l diltiazem. On day 7, cellular lipids were extracted and quantitated by thin layer chromatography. Lipid-laden cells, isolated from hypercholesterolemic rabbits (serum cholesterol levels, 300±9 mgl dl, mean ± SEM) were prepared as described in This study provides evidence for the first time that smooth muscle cells from arteries of patients receiving CCB therapy exhibit increased CE catabolic activities and reduction in cholesterol and CE mass. The data reported herein provides the basis for evidence that these agents, which are used widely in clinical practice, may also be useful as antiatherosclerotic agents in humans. The effects we report herein are independent of serum cholesterol levels or blood pressure, suggesting that our observations, in fact, are due to a direct cellular metabolic response to these agents.
Because a number of drugs administered to patients can affect calcium metabolism, the potential clinical implications of these studies are evident. There is, however, a paucity of studies related to the potential regression of atherosclerosis in humans by modulation of calcium flux over long periods of time. Specifically, there are no previous studies with calciumentry blockers. Thus, it will be important to determine whether these agents that interfere with calcium entry can also be effective in the process of atherosclerosis regression.
